Referências

1. Al-Ibraheem A., Et al., (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma, Cancer, 119, 6, pp. 1227-1234, (2013)
2. Annovazzi A., Et al., Diagnostic and clinical impact of 18F-FDG PET/CT in staging and restaging soft-tissue sarcomas of the extremities and trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center, Journal of Clinical Medicine, 9, 8, (2020)
3. Arndt C.A., Crist W.M., Common musculoskeletal tumors of childhood and adolescence, The New England Journal of Medicine United States, 341, 5, pp. 342-352, (1999)
4. Asadoorian M., Et al., Musculoskeletal pitfalls on fluorodeoxyglucose F 18 PET-computed tomography: Pictorial review, PET Clinics, 13, 4, pp. 587-607, (2018)
5. Baffour F.I., Wenger D.E., Broski S.M., (18)F-FDG PET/CT imaging features of lipomatous tumors, American Journal of Nuclear Medicine and Molecular Imaging, 10, 1, pp. 74-82, (2020)
6. Ben Arush M.W., Et al., Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities, Journal of Pediatric Hematology/Oncology, 28, 7, pp. 440-445, (2006)
7. Benz M.R., Et al., FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 8, pp. 2856-2863, (2009)
8. Berlin O., Et al., Surgery for soft tissue sarcoma in the extremities. A multivariate analysis of the 6-26-year prognosis in 137 patients, Acta Orthopaedica Scandinavica, 61, 6, pp. 475-486, (1990)
9. Boellaard R., Et al., FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0, European Journal of Nuclear Medicine and Molecular Imaging, 42, 2, pp. 328-354, (2015)
10. Brisson M., Et al., MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: Retrospective comparison with histology and MDM2 gene amplification, Skeletal Radiology, 42, 5, pp. 635-647, (2013)
11. Broski S.M., Et al., Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors, Skeletal Radiology, 45, 8, pp. 1097-1105, (2016)
12. Campbell K.M., Et al., Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review, Pediatric Blood & Cancer, (2020)
13. Casanova M., Et al., Soft-tissue sarcomas of the extremities in patients of pediatric age, Journal of Children's Orthopaedics, 1, 3, pp. 195-203, (2007)
14. Cecchetto G., Et al., Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: The experience of the Italian Cooperative Group studies, Cancer, 110, 11, pp. 2561-2567, (2007)
15. Chen B., Et al., Differentiation of soft tissue and bone sarcomas from benign lesions utilizing (18)F-FDG PET/CT-derived parameters, BMC Medical Imaging, 20, 1, (2020)
16. Choi J.H., Ro J.Y., Retroperitoneal sarcomas: An update on the diagnostic pathology approach, Diagnostics (Basel, Switzerland), 10, 9, (2020)
17. Chung W.J., Et al., MRI to differentiate benign from malignant soft-tissue tumours of the extremities: A simplified systematic imaging approach using depth, size and heterogeneity of signal intensity, The British Journal of Radiology, 85, 1018, pp. e831-e836, (2012)
18. Ciarallo A., Et al., Malignant perivascular epithelioid cell tumor (PEComa) of the uterus: Serial imaging with F-18 FDG PET/CT for surveillance of recurrence and evaluation of response to therapy, Clinical Nuclear Medicine, 36, 4, pp. e16-e19, (2011)
19. Cohen-Levy W.B., Et al., Significance of incidental intra-articular and peri-articular FDG avid foci on PET/CT, Acta Radiologica (Stockholm, Sweden: 1987), 60, 1, pp. 78-84, (2019)
20. Costantini D.L., Et al., Dual-time-point FDG PET/CT for the evaluation of pediatric tumors, AJR. American Journal of Roentgenology, 200, 2, pp. 408-413, (2013)
21. Dancheva Z., Et al., Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma, Nuclear Medicine Review. Central & Eastern Europe, 19, 1, pp. 22-27, (2016)
22. Dangoor A., Et al., UK guidelines for the management of soft tissue sarcomas, Clinical Sarcoma Research, 6, (2016)
23. de Marco L., Mamede M., Metabolic pattern of glomic tumor by F-18 FDG PET/CT, Clinical Nuclear Medicine, 36, 11, pp. 1051-1052, (2011)
24. Demetri G.D., Et al., Soft tissue sarcoma clinical practice guidelines in oncology, Journal of the National Comprehensive Cancer Network: JNCCN, 3, 2, pp. 158-194, (2005)
25. Demetri G.D., Et al., Soft tissue sarcoma, Journal of the National Comprehensive Cancer Network: JNCCN, 8, 6, pp. 630-674, (2010)
26. Diamantis A., Et al., Perioperative radiotherapy versus surgery alone for retroperitoneal sarcomas: A systematic review and meta-analysis, Radiology and Oncology, 54, 1, pp. 14-21, (2020)
27. Dimitrakopoulou-Strauss A., Et al., Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis, European Journal of Nuclear Medicine and Molecular Imaging, 37, 8, pp. 1481-1489, (2010)
28. Dong A., Et al., Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation, Clinical Nuclear Medicine, 39, 2, pp. 113-121, (2014)
29. Dundar A., Et al., Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: Importance of radiologic-pathologic correlation, Skeletal Radiology, 49, 3, pp. 483-489, (2020)
30. Eary J.F., Et al., Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis, European Journal of Nuclear Medicine and Molecular Imaging, 29, 9, pp. 1149-1154, (2002)
31. Eary J.F., Et al., Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome, Journal of Bone and Joint Surgery, 96, 2, pp. 152-158, (2014)
32. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology: Official Journal of the European Society for Medical Oncology, 25, pp. iii102-12, (2014)
33. Etchebehere E.C., Et al., Assessing the role of¹⁸F-FDG PET and¹⁸F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: A systematic review and meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, 43, 5, (2016)
34. Evilevitch V., Et al., Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14, 3, pp. 715-720, (2008)
35. Fiore M., Gronchi A., ASO author reflections: Evolving concepts for radiation therapy in extremity and trunk soft tissue sarcoma, Annals of Surgical Oncology, 25, pp. 942-943, (2018)
36. Gupta P., Et al., Spectrum of fat-containing soft-tissue masses at MR imaging: The common, the uncommon, the characteristic, and the sometimes confusing, Radiographics: A Review Publication of the Radiological Society of North America, Inc., 36, 3, pp. 753-766, (2016)
37. Hagi T., Et al., Is FDG-PET/CT useful for diagnosing pulmonary metastasis in patients with soft tissue sarcoma?, Anticancer Research, 38, 6, pp. 3635-3639, (2018)
38. Hanasilo C.E.H., Et al., Comparative study of planned and unplanned excisions for the treatment of soft tissue sarcoma of the extremities, Clinics (São Paulo, Brazil), 69, 9, pp. 579-584, (2014)
39. Harati K., Et al., Soft tissue sarcomas of the extremities: Surgical margins can be close as long as the resected tumor has no ink on it, The Oncologist, 22, 11, pp. 1400-1410, (2017)
40. Harrison D.J., Et al., PET with (18)F-fluorodeoxyglucose/computed tomography in the management of pediatric sarcoma, PET Clinics, 15, 3, pp. 333-347, (2020)
41. Ho K.-C., Et al., Presurgical identification of uterine smooth muscle malignancies through the characteristic FDG uptake pattern on PET scans, Contrast Media & Molecular Imaging, 2018, (2018)
42. Kallen M.E., Hornick J.L., The 2020 WHO classification: What's new in soft tissue tumor pathology?, The American Journal of Surgical Pathology, (2020)
43. Kandathil A., Subramaniam R.M., PET/computed tomography and precision medicine: Musculoskeletal sarcoma, PET Clinics, 12, 4, pp. 475-488, (2017)
44. Khiewvan B., Et al., The value of¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors, European Journal of Nuclear Medicine and Molecular Imaging, 41, 9, pp. 1756-1766, (2014)
45. Khoo C.Y., Et al., Systematic review of current prognostication systems for primary gastrointestinal stromal tumors, European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44, 4, pp. 388-394, (2018)
46. Kubo T., Et al., Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma
47. systematic review and meta-analysis, European Journal of Cancer (Oxford, England: 1990), 58, pp. 104-111, (2016)
48. Leal A.L., Et al., Evaluation of soft-tissue lesions with¹⁸F-FDG PET/CT: Initial results of a prospective trial, Nuclear Medicine Communications, 35, 3, (2014)
49. Lee J.-W., Et al., Preoperative [(18)F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: A multicentre retrospective study, European Journal of Nuclear Medicine and Molecular Imaging, 45, 8, pp. 1309-1316, (2018)
50. Levy A.D., Et al., Soft-tissue sarcomas of the abdomen and pelvis: Radiologic-pathologic features, part 1-common sarcomas: From the radiologic pathology archives, Radiographics: A Review Publication of the Radiological Society of North America, Inc, 37, 2, pp. 462-483, (2017)
51. Li J., Et al., Primary pulmonary artery sarcoma on dual-time point FDG PET/CT imaging, Clinical Nuclear Medicine, 41, 8, pp. 656-658, (2016)
52. Liu F., Et al., Performance of positron emission tomography and positron emission tomography/computed tomography using fluorine-18-fluorodeoxyglucose for the diagnosis, staging, and recurrence assessment of bone sarcoma: A systematic review and meta-analysis, Medicine, 94, 36, (2015)
53. Lodge M.A., Et al., A PET study of 18FDG uptake in soft tissue masses, European Journal of Nuclear Medicine, 26, 1, pp. 22-30, (1999)
54. Nair N., Basu S., Unsuspected metastatic male breast nodule from synovial sarcoma detected by FDG PET, Clinical Nuclear Medicine, 30, 4, pp. 289-290, (2005)
55. Nanni C., Fanti S., FDG-PET and PET/CT for evaluating soft tissue sarcomas, PET Clinics, 5, 3, pp. 341-347, (2010)
56. O'Donnell P.W., Et al., Can experienced observers differentiate between lipoma and well-differentiated liposarcoma using only MRI?, Sarcoma, 2013, (2013)
57. Papakonstantinou E., Et al., Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis, Journal of Bone Oncology, 25, (2020)
58. Parghane R.V., Basu S., Dual-time point (18)F-FDG-PET and PET/CT for differentiating benign from malignant musculoskeletal lesions: Opportunities and limitations, Seminars in Nuclear Medicine, 47, 4, pp. 373-391, (2017)
59. Patel S.A., Et al., Surveillance imaging patterns and outcomes following radiation therapy and radical Resection for localized extremity and trunk soft tissue sarcoma, Annals of Surgical Oncology, 24, 6, pp. 1588-1595, (2017)
60. Peeken J.C., Et al., Tumor grading of soft tissue sarcomas using MRI-based radiomics, eBioMedicine, 48, pp. 332-340, (2019)
61. Punt S.E.W., Et al., Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: Imaging characteristics, Nuclear Medicine Communications, 30, 7, pp. 546-549, (2009)
62. Riad S., Et al., Lymph node metastasis in soft tissue sarcoma in an extremity, Clinical Orthopaedics and Related Research, 426, pp. 129-134, (2004)
63. Roberge D., Et al., FDG PET/CT in initial staging of adult soft-tissue sarcoma, Sarcoma, 2012, (2012)
64. Roberts C.C., Et al., ACR appropriateness criteria follow-up of malignant or aggressive musculoskeletal tumors, Journal of the American College of Radiology: JACR, 13, 4, pp. 389-400, (2016)
65. Rusten E., Et al., Quantitative dynamic¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas, Acta oncologica (Stockholm, Sweden), 52, 6, pp. 1160-1167, (2013)
66. Ryan S., Et al., The value of MRI in distinguishing subtypes of lipomatous extremity tumors needs reassessment in the Era of MDM2 and CDK4 testing, Sarcoma, 2018, (2018)
67. Sa R., Et al., Utility of [(18)F] fluoro-deoxyglucose positron emission tomography/computed tomography for staging and therapy response evaluation in pediatric rhabdomyosarcoma: A case series and literature review, Frontiers in Medicine, 7, (2020)
68. Sadeghi R., Et al., Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: Systematic review and meta-analysis of the literature, International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 23, 8, pp. 1349-1356, (2013)
69. Salvatore B., Et al., Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?, Translational Medicine @ UniSa, 11, pp. 34-38, (2015)
70. Sambri A., Et al., The role of 18F-FDG PET/CT in soft tissue sarcoma, Nuclear Medicine Communications, 40, 6, pp. 626-631, (2019)
71. Santambrogio L., Et al., Primary pulmonary glomangioma: A coin lesion negative on PET study. Case report and literature review, The Thoracic and Cardiovascular Surgeon, 59, 6, pp. 380-382, (2011)
72. Seshadri N., Wright P., Balan K.K., Rhabdomyosarcoma with widespread bone marrow infiltration: Beneficial management role of F-18 FDG PET, Clinical Nuclear Medicine, 32, 10, pp. 787-789, (2007)
73. Shen G., Et al., Diffuse-type tenosynovial giant cell tumor of the thoracic spine: Appearance on FDG PET/CT, Clinical Nuclear Medicine, 44, 8, pp. e477-e478, (2019)
74. Shin D.-S., Et al., The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors, Annals of Nuclear Medicine, 22, 7, pp. 603-609, (2008)
75. Skamene S.R., Et al., Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas, Journal of Surgical Oncology, 109, 5, pp. 410-414, (2014)
76. Sun L., Et al., The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor, Oncotargets and Therapy, pp. 1967-1970, (2015)
77. Takahashi H., Et al., FDG-PET/CT demonstrates splenic angiosarcoma bone marrow metastasis, Clinical Nuclear Medicine, 45, 1, pp. e20-e23, (2020)
78. Takeuchi A., Et al., Tenosynovial giant cell tumors in unusual locations detected by positron emission tomography imaging confused with malignant tumors: Report of two cases, BMC Musculoskeletal Disorders, 17, (2016)
79. Tateishi U., Et al., Bone and soft-tissue sarcoma: Preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging, Radiology, 245, 3, pp. 839-847, (2007)
80. Volker T., Et al., Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 34, pp. 5435-5441, (2007)
81. von Mehren M., Et al., Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology, Journal of the National Comprehensive Cancer Network: JNCCN, 16, 5, pp. 536-563, (2018)
82. Wang S., Et al., A weighted scoring system to differentiate malignant liposarcomas from benign lipomas, Journal of Orthopaedic Surgery (Hong Kong), 24, 2, pp. 216-221, (2016)
83. Wang R., Et al., Primary common iliac artery angiosarcoma with multiple bone metastases revealed by dual-time point FDG PET/CT imaging, Clinical Nuclear Medicine, 44, 3, pp. 232-233, (2019)
84. Watanabe H., Et al., Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning, The Journal of Bone and Joint Surgery. British Volume, 82, 5, pp. 760-767, (2000)
85. Wu J., Et al., Malignant perivascular epithelioid cell tumor of lung on FDG PET/CT, Clinical Nuclear Medicine, 44, 6, pp. 469-471, (2019)
86. Xu H., Et al., Desmoid-type fibromatosis of the thorax: CT, MRI, and FDG PET characteristics in a large series from a tertiary referral center, Medicine, 94, 38, (2015)
87. Yadav D., Et al., Role of 18F-FDG PET/computed tomography in prognostication and management of malignant peripheral nerve sheath tumors, Nuclear Medicine Communications, 41, 9, pp. 924-932, (2020)
88. Yagci-Kupeli B., Et al., The value of 18F-FDG PET/CT in detecting bone marrow involvement in childhood cancers, Journal of Pediatric Hematology/Oncology, 41, 6, pp. 438-441, (2019)
89. Zhang H., Liu Q., Prognostic indicators for gastrointestinal stromal tumors: A review, Translational Oncology, 13, 10, (2020)